Table 5 Final model resulting from multinomial logistic regression for factors associated with unfavorable outcomes in new cases of drug-resistant pulmonary tuberculosis, Brazil, 2013 and 2014. (980 cases)
Lost to follow-up | Failure | Death | |||||||
|---|---|---|---|---|---|---|---|---|---|
Adjusted OR | (CI95%) | p value* | Adjusted OR | (CI95%) | p value* | Adjusted OR | (CI95%) | p value* | |
Block I | |||||||||
Race/color | |||||||||
White | 1.0 | 1.0 | 1.0 | ||||||
Brown/Black1 | 1.1 | (0.73–1.58) | 0.72 | 1.1 | (0.62–1.90) | 0.76 | 1.7 | (1.08–2.77) | 0.02 |
Asian/Indigenous | 0.8 | (0.08–6.77) | 0.80 | 0.99 | 0.99 | ||||
Age group (years) | |||||||||
15–59 | 1.0 | 1.0 | 1.0 | ||||||
60 or more | 0.4 | (0.18–1.09) | 0.08 | 1.1 | (0.44–2.82) | 0.81 | 3.4 | (1.90–6.03) | < 0.01 |
Education (years) | |||||||||
0 to 7 | 1.8 | (1.13–2.66) | 0.01 | 0.9 | (0.50–1.59) | 0.69 | 1.9 | (1.09–3.19) | 0.02 |
8 or more | 1.0 | 1.0 | 1.0 | ||||||
Missing | 1.8 | (0.89–3.62) | 0.10 | 0.6 | (0.17–1.90) | 0.36 | 2.8 | (1.27–6.02) | 0.01 |
HIV | |||||||||
Positive | 1.0 | (0.57–1.85) | 0.94 | 1.0 | (0.39–2.52) | 0.99 | 2.7 | (1.45–4.83) | < 0.01 |
Negative | 1.0 | 1.0 | 1.0 | ||||||
Missing | 1.2 | (0.66–2.02) | 0.61 | 0.8 | (0.36–1.97) | 0.70 | 1.5 | (0.79–2.76) | 0.22 |
Use of illicit drugs | |||||||||
Yes | 2.5 | (1.57–3.82) | < 0.01 | 0.9 | (0.41–2.06) | 0.84 | 1.3 | (0.73–2.38) | 0.37 |
No/don't know | 1.0 | 1.0 | 1.0 | ||||||
Prison population | |||||||||
Yes | 1.3 | (0.64–2.65) | 0.48 | 0.5 | (0.06–3.85) | 0.48 | 0.1 | (0.02–1.01) | 0.05 |
No/don't know | 1.0 | 1.0 | 1.0 | ||||||
Block II | |||||||||
Bilateral disease | |||||||||
Yes | 1.2 | (0.89–1.71) | 0.43 | 2.0 | (1.09–3.62) | 0.03 | 1.9 | (1.20–3.08) | 0.01 |
No | 1.0 | 1.0 | 1.0 | ||||||
Resistance type | |||||||||
Primary | 1.0 | 1.0 | 1.0 | ||||||
Acquired | 1.4 | (0.87–2.17) | 0.17 | 1.3 | (0.66–2.50) | 0.47 | 1.8 | (1.02–3.31) | 0.04 |
Initial resistance pattern | |||||||||
MDR/RR | 1.0 | 1.0 | 1.0 | ||||||
XDR | 0.7 | (0.07–6.25) | 0.73 | 1.5 | (0.22–9.69) | 0.70 | 7.3 | (1.97–27.09) | < 0.01 |
Injectable drug treatment | |||||||||
Only used Am | 1.0 | 1.0 | 1.0 | ||||||
Only used S | 0.9 | (0.58–1.38) | 0.61 | 1.0 | (0.51–1.90) | 0.97 | 0.8 | (0.52–1.38) | 0.50 |
Only use Cm | 1.4 | (0.59–3.24) | 0.46 | 1.7 | (0.51–5.55) | 0.40 | 0.8 | (0.25–2.61) | 0.73 |
Used more than one injectable or did not use | 0.9 | (0.36–2.13) | 0.76 | 2.8 | (1.05–7.69) | 0.04 | 1.5 | (0.60–3.61) | 0.40 |
Block III | |||||||||
Resides in different municipality than treatment | |||||||||
Yes | 0.7 | (0.46–0.99) | 0.04 | 1.7 | (0.97–2.92) | 0.07 | 0.8 | (0.54–1.31) | 0.45 |
No | 1.0 | 1.0 | 1.0 | ||||||
Reported unfavorable clinical evaluation | |||||||||
Yes | 3.1 | (2.02–4.86) | < 0.01 | 18.0 | (10.18–31.90) | < 0.01 | 3.3 | (2.02–5.44) | < 0.01 |
No | 1.0 | 1.0 | 1.0 | ||||||
Changed regimen type | |||||||||
Yes | 0.6 | (0.30–1.07) | 0.08 | 0.7 | (0.35–1.57) | 0.43 | 0.4 | (0.17–0.76) | 0.01 |
No | 1.0 | 1.0 | 1.0 | ||||||
Had adverse reaction | |||||||||
No adverse reaction records | 1.0 | 1.0 | 1.0 | ||||||
Only minor adverse reactions | 0.5 | (0.25–0.83) | 0.01 | 1.3 | (0.66–2.52) | 0.45 | 0.6 | (0.33–1.23) | 0.18 |
At least one major adverse reaction | 0.6 | (0.24–1.32) | 0.18 | 0.3 | (0.06–1.21) | 0.09 | 0.8 | (0.33–1.85) | 0.58 |